JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

86.08 3.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

85.5

Max

86.49

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-254M

-103M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+11.29% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.8B

13B

Ankstesnė atidarymo kaina

82.85

Ankstesnė uždarymo kaina

86.08

Naujienos nuotaikos

By Acuity

100%

0%

337 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-08 23:57; UTC

Rinkos pokalbiai

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

2026-02-08 23:47; UTC

Rinkos pokalbiai

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

2026-02-08 23:43; UTC

Rinkos pokalbiai

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-08 23:34; UTC

Rinkos pokalbiai

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

2026-02-08 23:26; UTC

Rinkos pokalbiai

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

2026-02-08 22:55; UTC

Uždarbis

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

2026-02-08 21:43; UTC

Rinkos pokalbiai

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

2026-02-08 21:16; UTC

Rinkos pokalbiai

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

2026-02-08 21:15; UTC

Rinkos pokalbiai

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-07 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-07 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-07 02:46; UTC

Įsigijimai, susijungimai, perėmimai

Big Money, High Anxiety -- Barrons.com

2026-02-06 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-06 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-06 21:40; UTC

Įsigijimai, susijungimai, perėmimai

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

2026-02-06 21:22; UTC

Rinkos pokalbiai

Mexico's Inflation Seen Accelerating in January -- Market Talk

2026-02-06 21:17; UTC

Uždarbis

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

2026-02-06 21:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-06 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

2026-02-06 21:13; UTC

Uždarbis

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

2026-02-06 21:13; UTC

Uždarbis

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

2026-02-06 21:04; UTC

Rinkos pokalbiai

Gold Closes Out Volatile Week on Higher Note -- Market Talk

2026-02-06 20:34; UTC

Uždarbis

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

11.29% į viršų

12 mėnesių prognozė

Vidutinis 96.27 USD  11.29%

Aukščiausias 110 USD

Žemiausias 87 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

12

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

337 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat